Haemonetics 3Q 2026: Revenue $357.76M, EPS $1 — 10-Q Summary

Mizuho raised its price target for Haemonetics (HAE) to $165 from $140, citing 18% organic plasma growth and improved guidance. The stock has gained 151% over the past year. HAE reported Q2 earnings of $1.35 per share, beating estimates, with revenue up 9.3% YoY. BTIG also raised its target to $142. Investors note margin guidance concerns and growth spending.

Haemonetics (HAE) reported Q2 FY 2027 organic revenue growth of 10% and 8% for the first half. The company expects FY 2027 organic growth of 6%-9% while expanding the CSL Persona PLUS rollout through 2027, according to management.

BTIG raised its price target on Haemonetics (HAE) to $142 from $130, maintaining a Buy rating. HAE's Q2 2027 revenue was $357.8M, up 9.3% YoY, beating estimates. Adjusted EPS was $1.35, exceeding expectations. All segments performed well, with Apheresis revenue at $204.8M. Adjusted gross margin increased to 61.9%. HAE raised fiscal 2027 revenue guidance but reduced adjusted EBIT margin expansion outlook.

Haemonetics [HAE] reported 10% organic revenue growth in Q2 2027 and 8% in H1, with adjusted EPS up 6% in both periods. The company raised FY27 revenue guidance but narrowed operating-margin expansion expectations due to capacity investments and cost pressures.

Haemonetics (HAE) reported Q2 fiscal 2027 revenue growth of 9.3% to $357.8M, with Apheresis up 12.6% and MedSurg up 5.1%. EPS rose 23% to $1.00. The company raised full-year revenue guidance to 8%-11% and organic growth to 6%-9%.

Haemonetics reported Q3 CY2026 revenue of $357.8M, beating estimates by 3.7% and growing 9.3% YoY. Adjusted EPS was $1.35, a 4.6% beat. Operating margin improved to 21% from 17.9% YoY, while free cash flow margin remained steady at 33.2%. Organic revenue rose 10% YoY.